Cargando…

Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito

BACKGROUND: The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in elderly women. Rikkunshito (RKT), a traditional Japanese medicine, acts as a prokinetic agent and improves gastric emptying and gastric accommodation. Our previous prospective randomized pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakata, Yasuhisa, Tominaga, Kazunari, Kato, Mototsugu, Takeda, Hiroshi, Shimoyama, Yasuyuki, Takeuchi, Toshihisa, Iwakiri, Ryuichi, Furuta, Kenji, Sakurai, Kouichi, Odaka, Takeo, Kusunoki, Hiroaki, Nagahara, Akihito, Iwakiri, Katsuhiko, Furuta, Takahisa, Murakami, Kazunari, Miwa, Hiroto, Kinoshita, Yoshikazu, Haruma, Ken, Takahashi, Shin’ichi, Watanabe, Sumio, Higuchi, Kazuhide, Fujimoto, Kazuma, Kusano, Motoyasu, Arakawa, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090183/
https://www.ncbi.nlm.nih.gov/pubmed/24990161
http://dx.doi.org/10.1186/1471-230X-14-116
_version_ 1782480598848241664
author Sakata, Yasuhisa
Tominaga, Kazunari
Kato, Mototsugu
Takeda, Hiroshi
Shimoyama, Yasuyuki
Takeuchi, Toshihisa
Iwakiri, Ryuichi
Furuta, Kenji
Sakurai, Kouichi
Odaka, Takeo
Kusunoki, Hiroaki
Nagahara, Akihito
Iwakiri, Katsuhiko
Furuta, Takahisa
Murakami, Kazunari
Miwa, Hiroto
Kinoshita, Yoshikazu
Haruma, Ken
Takahashi, Shin’ichi
Watanabe, Sumio
Higuchi, Kazuhide
Fujimoto, Kazuma
Kusano, Motoyasu
Arakawa, Tetsuo
author_facet Sakata, Yasuhisa
Tominaga, Kazunari
Kato, Mototsugu
Takeda, Hiroshi
Shimoyama, Yasuyuki
Takeuchi, Toshihisa
Iwakiri, Ryuichi
Furuta, Kenji
Sakurai, Kouichi
Odaka, Takeo
Kusunoki, Hiroaki
Nagahara, Akihito
Iwakiri, Katsuhiko
Furuta, Takahisa
Murakami, Kazunari
Miwa, Hiroto
Kinoshita, Yoshikazu
Haruma, Ken
Takahashi, Shin’ichi
Watanabe, Sumio
Higuchi, Kazuhide
Fujimoto, Kazuma
Kusano, Motoyasu
Arakawa, Tetsuo
author_sort Sakata, Yasuhisa
collection PubMed
description BACKGROUND: The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in elderly women. Rikkunshito (RKT), a traditional Japanese medicine, acts as a prokinetic agent and improves gastric emptying and gastric accommodation. Our previous prospective randomized placebo-controlled study showed that RKT combined with a standard-dose of rabeprazole (RPZ) significantly improved the acid-related dysmotility symptoms (ARD) in elderly patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD). This study aimed to evaluate clinical characteristics of elderly PPI-refractory NERD patients with ARD symptoms who responded to RKT. METHODS: Two hundred forty-two patients with PPI-refractory NERD were randomly assigned to 8 weeks of either RPZ (10 mg/q.d.) + RKT (7.5 g/t.i.d.) (RKT group) or RPZ + placebo (PL group). Among them, 95 were elderly (≥65 years) with ARD (RKT group: n = 52; PL group: n = 43). We analyzed the changes using the 12 subscale score of frequency scale for the symptoms of GERD (FSSG) and 15 items of the Gastrointestinal Symptom Rating Scale at 4 and 8 weeks and compared the therapeutic efficacy between the 2 groups. RESULTS: There were no marked differences in baseline demographic or clinical characteristics in the 2 groups except for rate of current smoking. The FSSG score (mean ± SD at 0, 4, and 8 weeks) in both the RKT (16.0 ± 7.0; 9.9 ± 8.4; 7.0 ± 6.4) and PL (15.1 ± 6.4; 10.9 ± 6.7, 11.1 ± 8.5) groups significantly decreased after treatment. However, the degree of improvement of total and ARD scores of FSSG after the 8-week treatment was significantly greater in the RKT group than in the PL group. Combination therapy with RKT for 8 weeks showed significant improvement in 3 subscale scores (abdominal bloating, heavy feeling in stomach and sick feeling after meals) of the ARD domain and 1 subscale score (heartburn after meals) of the reflux symptom domain. CONCLUSIONS: RKT may be useful for improving GERD symptoms in elderly PPI-refractory NERD patients with ARD. Thus, RKT was particularly effective for resolving postprandial GERD symptoms (heavy feeling in stomach, sick feeling, and heartburn after meals). TRIAL REGISTRATION: (UMIN000005880)
format Online
Article
Text
id pubmed-4090183
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40901832014-07-10 Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito Sakata, Yasuhisa Tominaga, Kazunari Kato, Mototsugu Takeda, Hiroshi Shimoyama, Yasuyuki Takeuchi, Toshihisa Iwakiri, Ryuichi Furuta, Kenji Sakurai, Kouichi Odaka, Takeo Kusunoki, Hiroaki Nagahara, Akihito Iwakiri, Katsuhiko Furuta, Takahisa Murakami, Kazunari Miwa, Hiroto Kinoshita, Yoshikazu Haruma, Ken Takahashi, Shin’ichi Watanabe, Sumio Higuchi, Kazuhide Fujimoto, Kazuma Kusano, Motoyasu Arakawa, Tetsuo BMC Gastroenterol Research Article BACKGROUND: The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in elderly women. Rikkunshito (RKT), a traditional Japanese medicine, acts as a prokinetic agent and improves gastric emptying and gastric accommodation. Our previous prospective randomized placebo-controlled study showed that RKT combined with a standard-dose of rabeprazole (RPZ) significantly improved the acid-related dysmotility symptoms (ARD) in elderly patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD). This study aimed to evaluate clinical characteristics of elderly PPI-refractory NERD patients with ARD symptoms who responded to RKT. METHODS: Two hundred forty-two patients with PPI-refractory NERD were randomly assigned to 8 weeks of either RPZ (10 mg/q.d.) + RKT (7.5 g/t.i.d.) (RKT group) or RPZ + placebo (PL group). Among them, 95 were elderly (≥65 years) with ARD (RKT group: n = 52; PL group: n = 43). We analyzed the changes using the 12 subscale score of frequency scale for the symptoms of GERD (FSSG) and 15 items of the Gastrointestinal Symptom Rating Scale at 4 and 8 weeks and compared the therapeutic efficacy between the 2 groups. RESULTS: There were no marked differences in baseline demographic or clinical characteristics in the 2 groups except for rate of current smoking. The FSSG score (mean ± SD at 0, 4, and 8 weeks) in both the RKT (16.0 ± 7.0; 9.9 ± 8.4; 7.0 ± 6.4) and PL (15.1 ± 6.4; 10.9 ± 6.7, 11.1 ± 8.5) groups significantly decreased after treatment. However, the degree of improvement of total and ARD scores of FSSG after the 8-week treatment was significantly greater in the RKT group than in the PL group. Combination therapy with RKT for 8 weeks showed significant improvement in 3 subscale scores (abdominal bloating, heavy feeling in stomach and sick feeling after meals) of the ARD domain and 1 subscale score (heartburn after meals) of the reflux symptom domain. CONCLUSIONS: RKT may be useful for improving GERD symptoms in elderly PPI-refractory NERD patients with ARD. Thus, RKT was particularly effective for resolving postprandial GERD symptoms (heavy feeling in stomach, sick feeling, and heartburn after meals). TRIAL REGISTRATION: (UMIN000005880) BioMed Central 2014-07-02 /pmc/articles/PMC4090183/ /pubmed/24990161 http://dx.doi.org/10.1186/1471-230X-14-116 Text en Copyright © 2014 Sakata et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sakata, Yasuhisa
Tominaga, Kazunari
Kato, Mototsugu
Takeda, Hiroshi
Shimoyama, Yasuyuki
Takeuchi, Toshihisa
Iwakiri, Ryuichi
Furuta, Kenji
Sakurai, Kouichi
Odaka, Takeo
Kusunoki, Hiroaki
Nagahara, Akihito
Iwakiri, Katsuhiko
Furuta, Takahisa
Murakami, Kazunari
Miwa, Hiroto
Kinoshita, Yoshikazu
Haruma, Ken
Takahashi, Shin’ichi
Watanabe, Sumio
Higuchi, Kazuhide
Fujimoto, Kazuma
Kusano, Motoyasu
Arakawa, Tetsuo
Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
title Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
title_full Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
title_fullStr Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
title_full_unstemmed Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
title_short Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
title_sort clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the g-pride study who responded to rikkunshito
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090183/
https://www.ncbi.nlm.nih.gov/pubmed/24990161
http://dx.doi.org/10.1186/1471-230X-14-116
work_keys_str_mv AT sakatayasuhisa clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT tominagakazunari clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT katomototsugu clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT takedahiroshi clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT shimoyamayasuyuki clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT takeuchitoshihisa clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT iwakiriryuichi clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT furutakenji clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT sakuraikouichi clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT odakatakeo clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT kusunokihiroaki clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT nagaharaakihito clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT iwakirikatsuhiko clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT furutatakahisa clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT murakamikazunari clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT miwahiroto clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT kinoshitayoshikazu clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT harumaken clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT takahashishinichi clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT watanabesumio clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT higuchikazuhide clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT fujimotokazuma clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT kusanomotoyasu clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito
AT arakawatetsuo clinicalcharacteristicsofelderlypatientswithprotonpumpinhibitorrefractorynonerosiverefluxdiseasefromthegpridestudywhorespondedtorikkunshito